Samsung Bio "Increase if Contracted"... Eli Lilly Expands Contract Manufacturing Volume

[Asia Economy Reporter Seo So-jung] Global pharmaceutical companies are continuously increasing their contract manufacturing organization (CMO) volumes with Samsung Biologics.

On the 19th, Samsung Biologics announced that Eli Lilly of the United States has revised its initial contract for biopharmaceutical contract manufacturing, signed in July, from $150 million to $268 million, an increase of $118 million. Eli Lilly has nearly doubled its contract volume with Samsung Biologics, demonstrating ongoing trust.

Not only Eli Lilly, but major global pharmaceutical companies are continuously expanding their existing contract manufacturing agreements with Samsung Biologics. According to Samsung Biologics, there have been a total of eight announced contract increases this year from companies such as Roche, Gilead, AstraZeneca, and TG Therapeutics. The total amount reaches 863.1 billion KRW.

In particular, Roche signed two consecutive contract increases last month, raising the contract size from 39.1 billion KRW to 444.4 billion KRW, more than a tenfold increase.

A Samsung Biologics representative stated, "Based on the series of contract increases from our clients, we achieved sales of 412.2 billion KRW in the second quarter of this year, followed by a record-breaking quarterly sales of 450.7 billion KRW in the third quarter. The fact that global pharmaceutical companies have significantly increased their production volumes with Samsung Biologics among various CMO providers is evidence of strong trust in our CMO services."

This content was produced with the assistance of AI translation services.